冠石科技：10月24日召开董事会会议

Group 1 - The core point of the article is that Guanshi Technology announced a board meeting to discuss the repurchase and cancellation of part of the restricted stock incentive plan for 2023 [1] - For the year 2024, Guanshi Technology's revenue composition is as follows: manufacturing accounts for 92.16%, trade accounts for 7.65%, and other businesses account for 0.19% [1] - As of the report date, Guanshi Technology has a market capitalization of 4 billion yuan [1] Group 2 - The article highlights that the Chinese innovative drug sector has sold overseas authorizations worth 80 billion USD this year [1] - There is a discussion on the hot secondary market for biomedicine, while the primary market is facing challenges in fundraising [1]